Clinical trials: Pancreas Carcinoma
Pancreatic Cancer
Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PACT-17 (NCT01167738)
- Testing
- capecitabine, cisplatin, epirubicin
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Carcinoma, Laparoscopic
Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma
Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC.
- Conditions
- Pancreatic Carcinoma, Laparoscopic, Pancreaticoduodenectomy
- Trial name
- NCT03785743
- Testing
- TLPD Surgery, OPD Surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Pancreatic Cancer
Preoperative Biliary Drainage in Malignant Biliary Obstruction
The first alarming symptom of a malignancy of the pancreas or periampullary tumor can be obstructive jaundice (OJ). Pancreato-duodenectomy (PD) combined with oncological treatment can provide long disease-free survival in…
- Trial name
- PEAR (NCT04847297)
- Testing
- Preoperative drainage and pancreatoduodenectomy, Pancreatoduodenectomy
- Volunteers
- 353 people
- Sponsor
- University of Pecs
Pancreatic Cancer, Pancreas Cancer
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
- Trial name
- NCT02950025
- Testing
- Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
This study was designed to determine the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advanced pancreatic cancer.
- Trial name
- PC1 (NCT02098291)
- Testing
- G17DT
- Volunteers
- 34 people
- Sponsor
- Cancer Advances Inc.
Hepatocarcinoma, Pancreatic Tumor
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
Hepatic (hepatocellular carcinoma (HCC)) and pancreatic (pancreatic adenocarcinoma (ADKP); pancreatic neuroendocrine tumors (TNEP)) primary tumors are the most common malignant tumors of the hepato-bilio-pancreatic system and…
- Trial name
- PROMETHEP (NCT05794048)
- Testing
- Hepatocellular carcinoma, Pancreatic adenocarcinoma, Pancreatic neuroendocrine tumor
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pancreatic Cancer, Pancreatic Neoplasm
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
This study will examine the safety and effectiveness of the drugs Gemcitabine and Herceptin, given in conjunction with radiation therapy, for treating patients with cancer of the pancreas.
- Trial name
- NCT00005926
- Testing
- Gemcitabine, Herceptin, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lung Carcinoma, Lower Oesophageal Carcinoma
Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition
The aim of high dose radiotherapy treatment is to deliver enough radiation to the tumour to kill all the cancer cells while at the same time giving a low dose of radiation to the normal parts of the body to reduce the side…
- Conditions
- Lung Carcinoma, Lower Oesophageal Carcinoma, Pancreatic Carcinoma
- Trial name
- NCT02285660
- Testing
- 4D PET-CT Scan, No intervention
- Where
- United Kingdom
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Pancreatic Cancer, Pancreatic Neoplasms
Intermittent Suction Technique in the Diagnosis of Pancreatic Solid Lesions
The aim of this study is to compare the diagnostic yield of intermittent versus continuous suction in the diagnosis of pancreatic solid lesions.
- Trial name
- NCT03829748
- Testing
- Intermittent aspiration
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Pancreatic Cancer
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
The safety and efficacy of combination of SBRT with sequential S-1 in treating patients with locally advanced pancreatic cancer and poor medical conditions will be evaluated.
- Trial name
- NCT02704143
- Testing
- combination of Cyberknife with S-1
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Changhai Hospital
Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Randomized phase II trial to compare the effectiveness of bortezomib with or without gemcitabine in treating patients who have metastatic pancreatic cancer.
- Trial name
- NCT00052689
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Insulinoma
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor.
- Trial name
- NCT04185350
- Testing
- 68Ga-NOTA-MAL-Cys39-exendin-4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pancreatic Cancer
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer…
- Trial name
- NCT00026338
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 173 sites in United States, Argentina and 17 more
- Volunteers
- 569 people
- Sponsor
- NCIC Clinical Trials Group
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
- Trial name
- NCT07539155
- Testing
- Intratumoral MMR Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Liver Cancer, Pancreatic Cancer
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
The goal of this clinical research study is to learn if there is a difference in patients' quality of recovery if they receive 1 of 2 standard kinds of pain control treatments after surgery on the liver and/or pancreas.
- Trial name
- NCT01438476
- Testing
- Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
This is a prospective, single arm, single center, phase II study of cadonilimab plus mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.
- Trial name
- NCT06153368
- Testing
- Cadonilimab+mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University
Metastatic Pancreatic Cancer
QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
Primary End Point: To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in patients with metastatic pancreatic cancer.
- Trial name
- NCT01796782
- Testing
- Xeloda, QYHJ Granules
- Volunteers
- 60 people
- Sponsor
- Fudan University